Analytical Data
-
Gene name
KIF18A
- Application
-
Alternative Names
MS-KIF18A; Marrow stromal KIF18A; Kinesin-like protein KIF18A
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q8NI77
-
Expression Region
Met1~Lys453
-
Molecular Weight
55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIF18A is a member of the kinesin superfamily of motor proteins, playing a crucial role in the transport of cellular cargo along microtubules, particularly during cell division. Understanding KIF18A is essential due to its involvement in mitotic processes, where it facilitates spindle assembly and chromosome alignment. Aberrant functioning of KIF18A has been linked to various cancers, making it a potential target for therapeutic interventions. The study of KIF18A recombinant proteins aims to elucidate its structure-function relationship, investigate its mechanistic role in mitosis, and develop inhibitors that could modulate its activity. By producing KIF18A in a recombinant system, researchers can obtain large quantities of the protein for structural analyses and functional assays. This research is fundamental to understanding its interactions with other cellular components and identifying its potential as a biomarker or a target in cancer treatment. Furthermore, insights gained from KIF18A studies could inform broader research on kinesin family proteins and their implications in cellular dynamics, providing a pathway for innovative therapeutic strategies.
